Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
Guillermo De Velasco, MD at Dana Farber discusses discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC
at ASCO GU 2016
Author: 2016_Genitourinary
Added: 03/03/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Toxicology